ZA200307831B - Modified protamine with reduced immunogenicity. - Google Patents
Modified protamine with reduced immunogenicity. Download PDFInfo
- Publication number
- ZA200307831B ZA200307831B ZA200307831A ZA200307831A ZA200307831B ZA 200307831 B ZA200307831 B ZA 200307831B ZA 200307831 A ZA200307831 A ZA 200307831A ZA 200307831 A ZA200307831 A ZA 200307831A ZA 200307831 B ZA200307831 B ZA 200307831B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino acid
- molecule
- peptide
- modified
- binding
- Prior art date
Links
- 102000007327 Protamines Human genes 0.000 title claims description 51
- 108010007568 Protamines Proteins 0.000 title claims description 51
- 229940048914 protamine Drugs 0.000 title claims description 43
- 230000005847 immunogenicity Effects 0.000 title claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 165
- 230000027455 binding Effects 0.000 claims description 85
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 77
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 70
- 102000004169 proteins and genes Human genes 0.000 claims description 68
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 58
- 150000001413 amino acids Chemical class 0.000 claims description 54
- 125000000539 amino acid group Chemical group 0.000 claims description 41
- 102000043131 MHC class II family Human genes 0.000 claims description 40
- 108091054438 MHC class II family Proteins 0.000 claims description 40
- 239000003446 ligand Substances 0.000 claims description 31
- 238000006467 substitution reaction Methods 0.000 claims description 30
- 230000006870 function Effects 0.000 claims description 29
- 229920001184 polypeptide Polymers 0.000 claims description 27
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 230000004071 biological effect Effects 0.000 claims description 21
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 17
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 17
- 230000004075 alteration Effects 0.000 claims description 13
- 230000002209 hydrophobic effect Effects 0.000 claims description 13
- 241000972773 Aulopiformes Species 0.000 claims description 11
- 230000002163 immunogen Effects 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 235000019515 salmon Nutrition 0.000 claims description 11
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 238000000126 in silico method Methods 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 230000009149 molecular binding Effects 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000008859 change Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 235000020616 amino acid formula Nutrition 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 66
- 235000001014 amino acid Nutrition 0.000 description 56
- 229940024606 amino acid Drugs 0.000 description 49
- 125000004429 atom Chemical group 0.000 description 40
- 229910052739 hydrogen Inorganic materials 0.000 description 28
- 239000001257 hydrogen Substances 0.000 description 28
- 230000003993 interaction Effects 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 18
- 230000028993 immune response Effects 0.000 description 10
- 108700028369 Alleles Proteins 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 238000004364 calculation method Methods 0.000 description 9
- 125000001931 aliphatic group Chemical group 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 7
- 229910052799 carbon Inorganic materials 0.000 description 7
- 238000000205 computational method Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 239000000370 acceptor Substances 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000002884 conformational search Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 108010016626 Dipeptides Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102100039350 Interferon alpha-7 Human genes 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000255964 Pieridae Species 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- -1 aromatic amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000009795 derivation Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000003032 molecular docking Methods 0.000 description 2
- 238000012900 molecular simulation Methods 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 1
- 101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 1
- 101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000386 donor Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 238000000324 molecular mechanic Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000002922 simulated annealing Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01105778 | 2001-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307831B true ZA200307831B (en) | 2004-07-21 |
Family
ID=8176722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307831A ZA200307831B (en) | 2001-03-08 | 2003-10-07 | Modified protamine with reduced immunogenicity. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040121443A1 (zh) |
| EP (1) | EP1411969A1 (zh) |
| JP (1) | JP2004520836A (zh) |
| KR (1) | KR20030082961A (zh) |
| CN (1) | CN1494430A (zh) |
| BR (1) | BR0207905A (zh) |
| CA (1) | CA2439929A1 (zh) |
| HU (1) | HUP0303430A3 (zh) |
| PL (1) | PL362699A1 (zh) |
| RU (1) | RU2003129062A (zh) |
| WO (1) | WO2002069997A1 (zh) |
| ZA (1) | ZA200307831B (zh) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090010966A1 (en) * | 2007-06-21 | 2009-01-08 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| US20090163437A1 (en) * | 2007-10-16 | 2009-06-25 | Regado Biosciences, Inc. | Steady-state subcutaneous administration of aptamers |
| EP2268297A4 (en) * | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| AU2010256511B2 (en) | 2009-06-03 | 2016-01-14 | Tobira Therapeutics, Inc. | Nucleic acid modulators of glycoprotein VI |
| WO2011034583A2 (en) | 2009-09-16 | 2011-03-24 | Duke University | Inhibition of endosomal toll-like receptor activation |
| US20120095085A1 (en) | 2010-10-14 | 2012-04-19 | Layzer Juliana M | Nucleic acid modulators of clec-2 |
| AU2012231268B2 (en) | 2011-03-18 | 2017-02-02 | Duke University | Peptides for suppressing inflammation |
| US9303063B2 (en) | 2011-03-18 | 2016-04-05 | Duke University | Peptide compounds for suppressing inflammation |
| CN102993290B (zh) * | 2012-12-12 | 2014-10-01 | 青岛亚博生物科技有限公司 | 反胶团法分离萃取鱼精蛋白 |
| US10059750B2 (en) | 2013-03-15 | 2018-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2685424B2 (ja) * | 1995-03-13 | 1997-12-03 | 日本水産株式会社 | プロタミンの製造方法 |
| US6624141B1 (en) * | 1999-03-17 | 2003-09-23 | The Regents Of The University Of Michigan | Protamine fragment compositions and methods of use |
-
2002
- 2002-03-01 PL PL02362699A patent/PL362699A1/xx unknown
- 2002-03-01 HU HU0303430A patent/HUP0303430A3/hu unknown
- 2002-03-01 JP JP2002569170A patent/JP2004520836A/ja not_active Withdrawn
- 2002-03-01 CN CNA028060652A patent/CN1494430A/zh active Pending
- 2002-03-01 CA CA002439929A patent/CA2439929A1/en not_active Abandoned
- 2002-03-01 EP EP02708339A patent/EP1411969A1/en not_active Withdrawn
- 2002-03-01 US US10/471,074 patent/US20040121443A1/en not_active Abandoned
- 2002-03-01 KR KR10-2003-7011660A patent/KR20030082961A/ko not_active Application Discontinuation
- 2002-03-01 RU RU2003129062/15A patent/RU2003129062A/ru not_active Application Discontinuation
- 2002-03-01 WO PCT/EP2002/002241 patent/WO2002069997A1/en not_active Application Discontinuation
- 2002-03-01 BR BR0207905-4A patent/BR0207905A/pt not_active IP Right Cessation
-
2003
- 2003-10-07 ZA ZA200307831A patent/ZA200307831B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002069997A1 (en) | 2002-09-12 |
| JP2004520836A (ja) | 2004-07-15 |
| CN1494430A (zh) | 2004-05-05 |
| CA2439929A1 (en) | 2002-09-12 |
| BR0207905A (pt) | 2004-07-27 |
| HUP0303430A2 (hu) | 2004-01-28 |
| US20040121443A1 (en) | 2004-06-24 |
| EP1411969A1 (en) | 2004-04-28 |
| RU2003129062A (ru) | 2005-04-10 |
| KR20030082961A (ko) | 2003-10-23 |
| PL362699A1 (en) | 2004-11-02 |
| HUP0303430A3 (en) | 2005-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040072291A1 (en) | Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity | |
| US20040072219A1 (en) | Modified leptin with reduced immunogenicity | |
| US20040063917A1 (en) | Modified erythropoietin (epo) with reduced immunogenicity | |
| US20040076991A1 (en) | Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity | |
| US7208147B2 (en) | Modified granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity | |
| US20040121443A1 (en) | Modified protamine with reduced immunogenicity | |
| US20040087503A1 (en) | Modified ciliary neurotrophic factor (cntf ) with reduced immunogenicity | |
| US20040063634A1 (en) | Modified kertinocyte growth factor (kgf) with reduced immunogenicity | |
| US20040062749A1 (en) | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity | |
| US20040071688A1 (en) | Modified thrombopoietin with reduced immunogenicity | |
| US20040096459A1 (en) | Modified insulin with reduced immunogenicity | |
| AU2002242715A1 (en) | Modified protamine with reduced immunogenicity | |
| AU2002229744A1 (en) | Modified interleukin-1 receptor antagonist (IL-1RA) with reduced immunogenicity | |
| AU2002257579A1 (en) | Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity | |
| AU2002238530A1 (en) | Modified human brain-derived neutrophic factor (BDNF) with reduced immunogenicity | |
| AU2002249180A1 (en) | Modified keratinocyte growth factor (KGF) with reduced immunogenicity | |
| AU2002254910A1 (en) | Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity | |
| AU2002250891A1 (en) | Modified leptin with reduced immunogenicity | |
| AU2002304824A1 (en) | Modified human granulocyte macrophage colony stimulating factor (GM-CSF) with reduced immunogenicity |